Halozyme Therapeutics HALO Change in Other Assets
Change in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's change in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's change in other assets?
- Halozyme Therapeutics (HALO) reported change in other assets of $9.11M in Q1 2026.
- How has Halozyme Therapeutics's change in other assets changed year-over-year?
- Halozyme Therapeutics's change in other assets increased by 82.3% year-over-year, from $5M to $9.11M.
- What does change in other assets mean?
- The change in miscellaneous short-term assets held by the company.
- How do you interpret change in other assets?
- Large fluctuations may indicate changes in prepaid expenses or other operational prepayments.
- How does change in other assets compare across companies?
- Standard line item; peers often group various small assets here, making it a catch-all for working capital adjustments.